Latigo Biotherapeutics, Inc.
LTGO
IPO
$22.76
-$0.04-0.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 62.42% | 105.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.24% | 8.94% | |||
| Operating Income | -0.24% | -8.94% | |||
| Income Before Tax | 0.15% | -9.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.15% | -9.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.15% | -9.59% | |||
| EBIT | -0.24% | -8.94% | |||
| EBITDA | -0.30% | -9.07% | |||
| EPS Basic | 24.45% | 5.72% | |||
| Normalized Basic EPS | 24.45% | 5.72% | |||
| EPS Diluted | 24.45% | 5.72% | |||
| Normalized Diluted EPS | 24.45% | 5.72% | |||
| Average Basic Shares Outstanding | 32.16% | 16.24% | |||
| Average Diluted Shares Outstanding | 32.16% | 16.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||